P2RY12 and cancer: Despite the possible antitumor effects of platelet inhibition via aspirin or P2Y12 inhibitors, the increased risk for bleeding using these products may limit their clinical usefulness in patients with cancer, thus necessitating the development of antiplatelet agents that do not produce the same bleeding risk.